Biopharma markets are never dull. The winners win big and the companies that lose are harshly penalized. Now the dust has settled, here's the final tally from Evaluate Pharma's review of biopharma markets in 2016.
Valeant was the talk of the town (or at least Union Square) on day two of the J.P. Morgan Healthcare Conference, announcing two divestitures worth $2.12 billion and unveiling a plan to pay down $5 billion in debt over the next 18 months.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Not even Valeant wants to be associated with Valeant anymore. The Canadian specialty drug company is reportedly considering a name change, while the rest of the industry works to distance itself from the price gouging practices.
Also, Gilead made a deal worth up to $1.2 billion to acquire drugs that treat NASH and liver cancer.
Elizabeth Wallner, diagnosed with Stage 4 colon cancer five years ago, has one word to describe the pharmaceutical executive who decided to double the price of Seconal: “Scumbag.”
Also, doctors still dislike direct-to-consumer genetics; Mayo will pay $1 billion for its EMR face-lift, and can we all admit we measure patient satisfaction incorrectly?
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
A high profile Super Bowl commercial by pharmaceutical company Valeant and the UK's health system pledged to spend $6.1 billion to go paperless and help shift patients with chronic conditions to remote monitoring.
Also, Martin Shkreli is fired, mixed messages on a digital health survey, and nurses remain America's most trusted people.
A lengthy takeout in the Wall Street Journal with a passive-aggressive headline is never a good sign.
Also, Valeant Pharmaceuticals creates a committee to probe its relationship with Philidor, Martin Shkreli does an (icky?) Reddit AMA, and there's a big move in cloud computing.
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
Valeant reacts to fallout over Citron report with conference call.
Also news on Cell Therapy, Spark Therapeutics and the quest for an electronic data standard.
AstraZeneca entered into a licensing agreement, valued at up to $445 million, for its experimental psoriasis drug.
Valeant Pharmaceuticals International Inc. increased its takeover offer for Salix Pharmaceuticals Inc. to $10.96 billion in cash, eliminating Endo International Plc. as a contender as a contender, which was the only other bidder for the maker of gastrointestinal drugs.